Medtronic, Inc. has gained CE Mark approval for its innovative Sentrino® Continuous Glucose Management System, the first minimally invasive continuous glucose monitoring (CGM) system specifically designed for use in hospital critical care units (CCU).
Glucose control is a standard practice in critical care units whether or not patients have diabetes because it improves outcomes. While it is a standard practice for diabetic and non-diabetic patients in the CCU, it’s difficult to achieve.
Continuous versus periodic monitoring reveals high and low glucose levels that periodic blood glucose testing might miss. This trending data allows clinicians to appropriately intervene to prevent glycemic excursions and maximise the patient’s time in the target range.
Medtronic says its Sentrino CGM System provides real-time trend data that serves as an early warning system, allowing clinicians to appropriately intervene to prevent glycemic excursions and maximise the patient’s time in the target range. In addition, the system integrates simply into the clinical workflow in the hospital to improve the quality and efficiency of maintaining glucose control.
“Introduction of the CGM technology in critically ill patients is a high priority that will help improve our insight in insulin resistance, will increase understanding of the effects of glycemic variability and will facilitate any blood glucose control strategy. Using the Sentrino CGM System for my intensive care patients will alert me to impending hypo or hyperglycemia, and will be invaluable in better maintaining glucose control,” said Prof. M.J. Schultz, MD, PhD, in the Intensive Care Medicine Department at Academisch Medisch Centrum (AMC) in Amsterdam.
“Despite its many benefits, good glycemic control is difficult to achieve in the CCU, and that’s why we developed Sentrino. Medtronic has a decade of CGM expertise, and we coupled it with extensive clinical research to develop the Sentrino CGM System for critically ill patients,” said Greg Meehan, vice president and general manager of the Continuous Glucose Monitoring business at Medtronic. “Given the market need for CGM in CCU patients, we believe the market potential will exceed $1 billion globally.”
Source: Medtronic, Inc.